This article is more than 5 years old. Information may no longer be current.

Surgeon: ‘Looking forward to implanting more’ accommodating IOLs

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

NEW YORK — Since the C&C Vision CrystaLens received a recommendation for Food and Drug Administration approval with conditions in May, one surgeon said he is “looking forward to implanting more of these” lenses.

Mark Packer, MD, presented the FDA trial results for the lenses here at the Ocular Surgery News Symposium on Cataract, Glaucoma and Refractive Surgery. Dr. Packer said the lens is under expedited review by the FDA, and final approval should come “soon.”

Dr. Packer said unlike multifocal lenses, where reduction of contrast sensitivity comes with an increase in glare, the CrystaLens shows contrast sensitivity improvement without glare.

He said in FDA studies the lens has shown “excellent visual outcomes” at distance, intermediate and near. He added that the accommodative effect seems to increase over time and is not affected by YAG capsulotomy, age, axial length or IOL power.

“Patient satisfaction also is high,” Dr. Packer said.